Back to Journals » Biologics: Targets and Therapy » Volume 7

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]

Authors Keohane C, Radia DH, Harrison CN

Received 6 September 2013

Accepted for publication 6 September 2013

Published 31 October 2013 Volume 2013:7 Pages 231—232

DOI https://doi.org/10.2147/BTT.S54093

Keohane C, Radia DH, Harrison CN. Biologics: Targets and Therapy. 2013;7:189–198.

On page 193 note that the paragraph beginning "Pacritinib (SB1518; Cell Technology, Inc, Mountain View, CA, USA) is a JAK2 and FLT3 inhibitor currently being evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts (<50 × 109/L)." should have been "Pacritinib (SB1518; Cell Therapeutics, Inc, Seattle, WA, USA) is a JAK2 and FLT3 inhibitor which was evaluated at a dose of 400 mg daily in a Phase II study (N=34) that included patients with low platelet counts (<50 × 109/L)."
On page 193 in the same paragraph note that "Post-Essential Thrombocythemia Myelofibrosis: PERSIST)." should have been "Post-Essential Thrombocythemia Myelofibrosis-1: PERSIST-1)."

Read the original article

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]